New drug combo takes on Hard-to-Treat cancers in first human test

NCT ID NCT06724016

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called HM16390, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and check for early signs of effectiveness. About 292 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HM16390 (an experimental drug) and pembrolizumab (Keytruda, an immunotherapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, first-in-human trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, 05505, South Korea
Karmanos Cancer Institute
NOT_YET_RECRUITING

Detroit, Michigan, 48201, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.